BioMarin Pharmaceutical Inc. Securities Litigation

If you purchased a significant amount of shares of BioMarin Pharmaceutical Inc. Common Stock (NASDAQ: BMRN), you have certain options. Investors should register for updates.


Lawsuit Overview

Defendant:BioMarin Pharmaceutical Inc. Common Stock
Date Filed:September 25th, 2020
Sector:Health Care
Industry:Major Pharmaceuticals
Class Start Date:February 28th, 2020
Class End Date:August 18th, 2020

According to the Complaint, BioMarin Pharmaceutical Inc. is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The Company's product candidates include, among others, valoctocogene roxaparvovec, an investigational AAV gene therapy, which is in Phase 3 clinical development for the treatment of patients with severe hemophilia A.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operational, and compliance policies. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec's durability of effect; (ii) as a result, it was foreseeable that the FDA would not approve the BLA for valoctocogene roxaparvovec without additional data; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for BioMarin Pharmaceutical Inc. Common Stock

First Identified Complaint

Bill Tsantes, et al. v. BioMarin Pharmaceutical Inc., et al.

Date Filed:September 25th, 2020
Class Period Start:February 28th, 2020
Class Period End:August 18th, 2020
First Identified Complaint Filings
#Document TitleFiling Date